NCPC, a leading pharmaceutical manufacturer, proudly announced the unveiling of its enhanced EP-grade Procaine Penicillin at a prestigious healthcare exhibition.

This long-acting antibiotic, a procaine salt of penicillin, boasts improved bioavailability and sustained release, making it an ideal choice for treating a wide range of bacterial infections.

The EP-grade Procaine Penicillin from NCPC adheres to the highest international standards of purity and efficacy, ensuring consistent clinical outcomes.

Its efficacy spans from treating mild to moderate infections caused by penicillin-sensitive pathogens, including streptococcal infections, to more complex cases like early syphilis and rheumatic fever.

With its ability to inhibit bacterial cell wall synthesis, the antibiotic offers robust protection against a broad spectrum of microorganisms, including Gram-positive and selected Gram-negative bacteria.

NCPC's dedication to innovation and quality ensures that this EP-grade Procaine Penicillin remains a trusted solution for healthcare professionals worldwide.

The announcement underscores NCPC's commitment to advancing global healthcare through the development and distribution of high-quality pharmaceutical products.